Hanall Biopharma Co., Ltd. (KRX: 009420)
South Korea
· Delayed Price · Currency is KRW
39,950
-1,200 (-2.92%)
Jan 31, 2025, 11:54 AM KST
Hanall Biopharma Revenue
Hanall Biopharma had revenue of 36.84B KRW in the quarter ending September 30, 2024, with 11.74% growth. This brings the company's revenue in the last twelve months to 134.24B, up 0.70% year-over-year. In the year 2023, Hanall Biopharma had annual revenue of 134.91B with 22.65% growth.
Revenue (ttm)
134.24B
Revenue Growth
+0.70%
P/S Ratio
15.35
Revenue / Employee
434.45M
Employees
309
Market Cap
2,061.37B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 134.91B | 24.91B | 22.65% |
Dec 31, 2022 | 110.00B | 8.40B | 8.27% |
Dec 31, 2021 | 101.59B | 12.99B | 14.66% |
Dec 31, 2020 | 88.60B | -19.85B | -18.30% |
Dec 31, 2019 | 108.45B | 16.61B | 18.09% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,364.39B |
Celltrion | 2,876.25B |
Yuhan | 2,008.84B |
SK Biopharmaceuticals | 511.33B |
SK bioscience | 201.30B |
Hanmi Pharm. | 1,566.25B |
Hanmi Science | 1,283.65B |
Daewoong Pharmaceutical | 1,416.63B |